In a pioneering approach to artificial organ development, engineers at Draper Laboratory in Cambridge, Mass., are applying semiconductor manufacturing technology to the development of artificial organs such as lungs and kidneys.
Intricate internal structures produced via micro-electromechanical systems (MEMS) are being tested as vascular systems that could oxygenate a person's blood during surgery. They also could function down the road as part of an implantable device.
"This is important because oxygenators currently used during heart surgery use a significant amount of anticoagulants," says Dr. Jeffrey Borenstein, principal investigator in the tissue engineering research being conducted at Draper.
Most artificial lung devices used today consist of hollow, porous fiber bundles inside a hard-shelled jacket. Oxygen is introduced through the fibers and diffused into blood flowing around the fibers. This process often damages the blood for maximum membrane exposure.
Adverse interactions between the blood and device materials such as polyethersulfone may cause clotting. Preventing this requires a high level of anticoagulants, which can cause excessive bleeding and other problems for the patient.
Doctors at leading Boston teaching hospitals approached Borenstein and asked if Draper could research technologies to replace current oxygenating devices. The doctors were part of CIMIT, the Center for Integration of Medicine and Innovative Technology.
The idea was that microfabrication technology developed at Draper for sensors used in defense, aerospace, and commercial products such as digital cameras and the Nintendo Wii game controller might help create an artificial lung with microchannels that mimic the blood vessels in human organs.
The story continues on page 2; please click below.
Fascinating video and story. In addition to the obviously important medical applications, it''d be interesting to see if these micromechanical structures, which support the interchange between two fluids, or a fluid and gas, have other applications in processes, such as the manufacture of pharmaceuticals or other chemicals.
Californiaís plan to mandate an electric vehicle market isnít the first such undertaking and certainly wonít be the last. But as the Golden State ratchets up for its next big step toward zero-emission vehicle status in 2018, it might be wise to consider a bit of history.